Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This trial is a multicenter, open-label, randomized, Phase III study in patients with
recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial
platinum-based chemotherapy. Patients will receive either Docetaxel or Pemetrexed as
chemotherapy at the investigator's choice. Within each chemotherapy group, patients will be
randomized to receive Cetuximab plus chemotherapy or chemotherapy alone (Cetuximab &
Pemetrexed or Pemetrexed alone; Cetuximab & Docetaxel or Docetaxel alone).